

# Michele P Lambert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7390974/publications.pdf>

Version: 2024-02-01

139  
papers

5,085  
citations

109137

35  
h-index

98622

67  
g-index

141  
all docs

141  
docs citations

141  
times ranked

8390  
citing authors

#	ARTICLE	IF	CITATIONS
1	Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. <i>Nature Medicine</i> , 2014, 20, 1315-1320.	15.2	483
2	Comprehensive Rare Variant Analysis via Whole-Genome Sequencing to Determine the Molecular Pathology of Inherited Retinal Disease. <i>American Journal of Human Genetics</i> , 2017, 100, 75-90.	2.6	343
3	Thrombocytopenia following Pfizer and Moderna <sc>SARS-CoV-2</sc> vaccination. <i>American Journal of Hematology</i> , 2021, 96, 534-537.	2.0	331
4	Clinical updates in adult immune thrombocytopenia. <i>Blood</i> , 2017, 129, 2829-2835.	0.6	315
5	Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. <i>Blood</i> , 2016, 127, 17-28.	0.6	165
6	A high-throughput sequencing test for diagnosing inherited bleeding, thrombotic, and platelet disorders. <i>Blood</i> , 2016, 127, 2791-2803.	0.6	157
7	Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. <i>Lancet Haematology</i> , 2015, 2, e315-e325.	2.2	146
8	Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. <i>American Journal of Human Genetics</i> , 2016, 98, 1051-1066.	2.6	137
9	A gain-of-function variant in DIAPH1 causes dominant macrothrombocytopenia and hearing loss. <i>Blood</i> , 2016, 127, 2903-2914.	0.6	121
10	Human phenotype ontology annotation and cluster analysis to unravel genetic defects in 707 cases with unexplained bleeding and platelet disorders. <i>Genome Medicine</i> , 2015, 7, 36.	3.6	119
11	Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1482-1495.	1.5	116
12	Neutrophil accumulation and NET release contribute to thrombosis in HIT. <i>JCI Insight</i> , 2018, 3, .	2.3	115
13	Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. <i>Blood</i> , 2007, 110, 1153-1160.	0.6	107
14	What is new with 22q? An update from the 22q and You Center at the Children's Hospital of Philadelphia. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2058-2069.	0.7	106
15	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. <i>Blood Advances</i> , 2020, 4, 6051-6063.	2.5	105
16	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. <i>Haematologica</i> , 2017, 102, 1192-1203.	1.7	92
17	A dominant gain-of-function mutation in universal tyrosine kinase <i>SRC</i> causes thrombocytopenia, myelofibrosis, bleeding, and bone pathologies. <i>Science Translational Medicine</i> , 2016, 8, 328ra30.	5.8	87
18	Defects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg <sup>2+</sup> homeostasis and cytoskeletal architecture. <i>Nature Communications</i> , 2016, 7, 11097.	5.8	84

#	ARTICLE	IF	CITATIONS
19	Challenges and promises for the development of donor-independent platelet transfusions. <i>Blood</i> , 2013, 121, 3319-3324.	0.6	78
20	Eltrombopag for use in children with immune thrombocytopenia. <i>Blood Advances</i> , 2018, 2, 454-461.	2.5	75
21	Glanzmann thrombasthenia: genetic basis and clinical correlates. <i>Haematologica</i> , 2020, 105, 888-894.	1.7	75
22	Diagnosis and Management of Autoimmune Cytopenias in Childhood. <i>Pediatric Clinics of North America</i> , 2013, 60, 1489-1511.	0.9	74
23	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1407-1413.	0.8	70
24	Patients with common variable immunodeficiency with autoimmune cytopenias exhibit hyperplastic yet inefficient germinal center responses. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 258-265.	1.5	68
25	A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. <i>Pediatric Blood and Cancer</i> , 2008, 50, 223-226.	0.8	66
26	High-level transgene expression in induced pluripotent stem cell-derived megakaryocytes: correction of Glanzmann thrombasthenia. <i>Blood</i> , 2014, 123, 753-757.	0.6	54
27	Platelet factor 4 regulates megakaryopoiesis through low-density lipoprotein receptor-related protein 1 (LRP1) on megakaryocytes. <i>Blood</i> , 2009, 114, 2290-2298.	0.6	51
28	RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME). <i>Transfusion</i> , 2012, 52, 1126-1136.	0.8	49
29	GNE variants causing autosomal recessive macrothrombocytopenia without associated muscle wasting. <i>Blood</i> , 2018, 132, 1851-1854.	0.6	48
30	The 22q11.2 deletion syndrome: Cancer predisposition, platelet abnormalities and cytopenias. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2121-2127.	0.7	47
31	Chemokines and thrombogenicity. <i>Thrombosis and Haemostasis</i> , 2007, 97, 722-729.	1.8	43
32	Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. <i>Nature Communications</i> , 2021, 12, 7222.	5.8	41
33	Platelets in liver and renal disease. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 251-255.	0.9	39
34	Endogenous platelet factor 4 stimulates activated protein C generation in vivo and improves survival after thrombin or lipopolysaccharide challenge. <i>Blood</i> , 2007, 110, 1903-1905.	0.6	38
35	Myosin-II repression favors pre/proplatelets but shear activation generates platelets and fails in macrothrombocytopenia. <i>Blood</i> , 2015, 125, 525-533.	0.6	38
36	Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding. <i>Blood</i> , 2017, 130, 1026-1030.	0.6	38

#	ARTICLE	IF	CITATIONS
37	Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. <i>American Journal of Hematology</i> , 2019, 94, 741-750.	2.0	37
38	Convalescent plasma for pediatric patients with SARS-CoV-2-associated acute respiratory distress syndrome. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28693.	0.8	37
39	What To Do When You Suspect an Inherited Platelet Disorder. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 377-383.	0.9	33
40	Therapy induced iron deficiency in children treated with eltrombopag for immune thrombocytopenia. <i>American Journal of Hematology</i> , 2017, 92, E88-E91.	2.0	33
41	AAV-8 and AAV-9 Vectors Cooperate with Serum Proteins Differently Than AAV-1 and AAV-6. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 10, 291-302.	1.8	33
42	Physician decision making in selection of second-line treatments in immune thrombocytopenia in children. <i>American Journal of Hematology</i> , 2018, 93, 882-888.	2.0	30
43	22q and two: 22q11.2 deletion syndrome and coexisting conditions. <i>American Journal of Medical Genetics, Part A</i> , 2018, 176, 2203-2214.	0.7	30
44	Next-generation sequencing for the diagnosis of MYH9: Predicting pathogenic variants. <i>Human Mutation</i> , 2020, 41, 277-290.	1.1	30
45	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2012, 58, 221-225.	0.8	29
46	Utility of the immature platelet fraction in pediatric immune thrombocytopenia: Differentiating from bone marrow failure and predicting bleeding risk. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26812.	0.8	27
47	Multicenter Cohort Study Comparing U.S. Management of Inpatient Pediatric Immune Thrombocytopenia to Current Treatment Guidelines. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1227-1231.	0.8	26
48	Inherited Platelet Disorders. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 471-487.	0.9	25
49	A chimeric platelet-targeted urokinase prodrug selectively blocks new thrombus formation. <i>Journal of Clinical Investigation</i> , 2015, 126, 483-494.	3.9	25
50	Chemotherapy induced thrombocytopenia in pediatric oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 299-307.	2.0	24
51	Utility and limitations of exome sequencing in the molecular diagnosis of pediatric inherited platelet disorders. <i>American Journal of Hematology</i> , 2018, 93, 8-16.	2.0	22
52	Common variable immunodeficiency-associated endotoxemia promotes early commitment to the T follicular lineage. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1660-1673.	1.5	22
53	Dysregulation of PLDN (pallidin) is a mechanism for platelet dense granule deficiency in RUNX1 haploinsufficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 792-801.	1.9	21
54	Influence of the American Society of Hematology Guidelines on the Management of Newly Diagnosed Childhood Immune Thrombocytopenia. <i>JAMA Pediatrics</i> , 2014, 168, e142214.	3.3	20

#	ARTICLE	IF	CITATIONS
55	Apoptotic effects of platelet factor V <sup>III</sup> on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2102-2112.	1.9	20
56	Specifications of the variant curation guidelines for <i>ITGA2B</i> / <i>ITGB3</i> : ClinGen Platelet Disorder Variant Curation Panel. <i>Blood Advances</i> , 2021, 5, 414-431.	2.5	19
57	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1364-1371.	1.9	19
58	Sports Participation in Children and Adolescents with Immune Thrombocytopenia (ITP). <i>Pediatric Blood and Cancer</i> , 2015, 62, 2223-2225.	0.8	18
59	Fatigue in children and adolescents with immune thrombocytopenia. <i>British Journal of Haematology</i> , 2020, 191, 98-106.	1.2	18
60	A novel mutation in MPL (Y252H) results in increased thrombopoietin sensitivity in essential thrombocythemia. <i>American Journal of Hematology</i> , 2012, 87, 532-534.	2.0	17
61	Defective RAB1B-related megakaryocytic ER-to-Golgi transport in RUNX1 haplodeficiency: impact on von Willebrand factor. <i>Blood Advances</i> , 2018, 2, 797-806.	2.5	17
62	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell-associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. <i>Clinical Cancer Research</i> , 2022, 28, 3804-3813.	3.2	17
63	Intramedullary megakaryocytes internalize released platelet factor 4 and store it in alpha granules. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1888-1899.	1.9	16
64	Current status of blood "pharming". <i>Current Opinion in Hematology</i> , 2017, 24, 565-571.	1.2	16
65	The Role of Platelet Factor 4 in Radiation-Induced Thrombocytopenia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1533-1540.	0.4	15
66	Distinct immune trajectories in patients with chromosome 22q11.2 deletion syndrome and immune-mediated diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 445-450.	1.5	15
67	The incidence of thrombocytopenia in children with Cornelia de Lange syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2011, 155, 33-37.	0.7	14
68	Update on the inherited platelet disorders. <i>Current Opinion in Hematology</i> , 2015, 22, 460-466.	1.2	13
69	Population based frequency of naturally occurring loss-of-function variants in genes associated with platelet disorders. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 248-254.	1.9	13
70	Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 69-80.	1.0	13
71	2-O, 3-O-Desulfated Heparin (ODSH) Mitigates Chemotherapy-Induced Thrombocytopenia (CIT) by Blocking the Negative Paracrine Effect of Platelet Factor 4 (PF4) On Megakaryopoiesis. <i>Blood</i> , 2012, 120, 386-386.	0.6	13
72	Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29026.	0.8	11

#	ARTICLE	IF	CITATIONS
73	Presentation and diagnosis of autoimmune lymphoproliferative syndrome (ALPS). Expert Review of Clinical Immunology, 2021, 17, 1163-1173.	1.3	11
74	Diagnostic Challenges in Pediatric Hemophagocytic Lymphohistiocytosis. Journal of Clinical Immunology, 2021, 41, 1213-1218.	2.0	10
75	Rapid Evaluation of Platelet Function With T2 Magnetic Resonance. American Journal of Clinical Pathology, 2016, 146, 681-693.	0.4	9
76	2-O, 3-O desulfated heparin mitigates murine chemotherapy- and radiation-induced thrombocytopenia. Blood Advances, 2018, 2, 754-761.	2.5	9
77	Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. European Journal of Haematology, 2021, 106, 783-787.	1.1	9
78	Platelets and eltrombopag: a not-so-sticky situation. Blood, 2012, 119, 3876-3877.	0.6	8
79	Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review. American Journal of Hematology, 2019, 94, 461-466.	2.0	8
80	Human mutational constraint as a tool to understand biology of rare and emerging bone marrow failure syndromes. Blood Advances, 2020, 4, 5232-5245.	2.5	8
81	An Update on Pediatric Immune Thrombocytopenia (ITP): Differentiating Primary ITP, IPD, and PID. Blood, 2021, , .	0.6	8
82	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. Blood, 2015, 126, 73-73.	0.6	6
83	MYH9-macrothrombocytopenia caused by a novel variant (E1421K) initially presenting as apparent neonatal alloimmune thrombocytopenia. Pediatric Blood and Cancer, 2018, 65, e26949.	0.8	5
84	Extreme thrombocytosis is associated with critical illness and young age, but not increased thrombotic risk, in hospitalized pediatric patients. Journal of Thrombosis and Haemostasis, 2020, 18, 3352-3358.	1.9	5
85	Racial variation in ITP prevalence and chronic disease phenotype suggests biological differences. Blood, 2020, 136, 640-643.	0.6	5
86	Platelet factor 4 platelet levels are inversely correlated with steady-state platelet counts and with platelet transfusion needs in pediatric leukemia patients. Journal of Thrombosis and Haemostasis, 2012, 10, 1442-1446.	1.9	4
87	They're not your daddy's inherited platelet disorders anymore. Journal of Thrombosis and Haemostasis, 2013, 11, 2037-2038.	1.9	4
88	Standardization of prophylactic platelet transfusion dosing in a pediatric oncology population: a quality improvement project. Transfusion, 2018, 58, 2836-2840.	0.8	4
89	Immunomodulatory Second-Line Therapies for Immune Thrombocytopenia. Hamostaseologie, 2019, 39, 266-271.	0.9	4
90	Genetic variants in toll-like receptor 4 are associated with lack of steroid responsiveness in pediatric ITP patients. American Journal of Hematology, 2020, 95, 395-400.	2.0	4

#	ARTICLE	IF	CITATIONS
91	Quality of life is an important indication for secondâ€line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29023.	0.8	4
92	Updates in diagnosis of the inherited platelet disorders. <i>Current Opinion in Hematology</i> , 2020, 27, 333-340.	1.2	3
93	Thrombocytosis in an infant with a <i>TRPV4</i> mutation: a case report. <i>Platelets</i> , 2021, 32, 429-431.	1.1	3
94	SARSâ€CoVâ€2 vaccination in pediatric patients with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29760.	0.8	3
95	Defective RAB31-mediated megakaryocytic early endosomal trafficking of VWF, EGFR, and M6PR in <i>RUNX1</i> deficiency. <i>Blood Advances</i> , 2022, 6, 5100-5112.	2.5	3
96	TPO-mimetics and myelofibrosis? A reticulin question!. <i>Blood</i> , 2009, 114, 3722-3723.	0.6	2
97	More than one pathway: novel treatment for ITP. <i>Blood</i> , 2019, 133, 629-630.	0.6	2
98	Intravenous immunoglobulin use in children with ITP does not affect development of chronic disease. <i>Journal of Pediatrics</i> , 2019, 204, 320-323.	0.9	2
99	Improving interpretation of genetic testing for hereditary hemorrhagic, thrombotic, and platelet disorders. <i>Hematology American Society of Hematology Education Program</i> , 2020, 2020, 76-81.	0.9	2
100	Report of a â€consensusâ€™ on the lines of therapy for primary immune thrombocytopenia in adults, promoted by the Italian Gruppo di Studio delle Piastrine. <i>Platelets</i> , 2020, 31, 461-473.	1.1	2
101	Negative Paracrine Effect of Platelet Factor 4 on Megakaryopoiesis Occurs through Lipoprotein Related Protein Receptor-1 on Megakaryocytes.. <i>Blood</i> , 2007, 110, 97-97.	0.6	2
102	Megakaryocytes Regulate Hematopoietic Stem Cell Quiescence Via PF4 Secretion. <i>Blood</i> , 2013, 122, 3-3.	0.6	2
103	Targeting mTOR Signaling Leads To Complete and Durable Responses In Children With Multi-Lineage Autoimmune Cytopenias, Including ALPS, SLE, Evans and CVID. <i>Blood</i> , 2013, 122, 330-330.	0.6	2
104	Megakaryocytes Exchange Significant Levels of Their Alpha-Granular PF4 with Their Environment. <i>Blood</i> , 2014, 124, 1432-1432.	0.6	2
105	Honing in on the Range: Using the Electronic Medical Record to Establish Normal Reference Ranges for Pediatric Coagulation Testing. <i>Blood</i> , 2015, 126, 4450-4450.	0.6	2
106	The Immature Reticulocyte Fraction As an Aid in the Diagnosis and Prognosis of Parvovirus B19 Infection in Sickle Cell Disease. <i>Blood</i> , 2018, 132, 3678-3678.	0.6	2
107	Childhood ITP: knowing when to worry?. <i>Blood</i> , 2009, 114, 4758-4759.	0.6	1
108	Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia. <i>Pediatric Health, Medicine and Therapeutics</i> , 2016, 7, 39.	0.7	1

#	ARTICLE	IF	CITATIONS
109	Neonatal platelet count trends during inhaled nitric oxide therapy. <i>British Journal of Haematology</i> , 2020, 188, e28-e30.	1.2	1
110	Thromboelastography Changes of Whole Blood Compared to Blood Component Transfusion in Infant Craniosynostosis Surgery. <i>Journal of Craniofacial Surgery</i> , 2022, 33, 129-133.	0.3	1
111	Inherited Thrombocytopenias. , 2007, , 985-998.		1
112	RAB31-Mediated Endosomal Trafficking Is Defective in RUNX1 Haplodeficiency. <i>Blood</i> , 2018, 132, 519-519.	0.6	1
113	The ITP Natural History Study Registry: Preliminary Findings on the Immune Thrombocytopenia Patient Experience. <i>Blood</i> , 2018, 132, 4979-4979.	0.6	1
114	Can Immature Platelet Fraction (IPF) be Used to Assess Bleeding Risk in Pediatric Immune Thrombocytopenia (ITP) and to Differentiate ITP from Bone Marrow Failure/Aplastic Anemia? A Retrospective Analysis. <i>Blood</i> , 2015, 126, 3474-3474.	0.6	1
115	Utility of Whole Exome Sequencing in Diagnosis of Pediatric Platelet Disorders: A Subanalysis of the Pediseq Study. <i>Blood</i> , 2016, 128, 3726-3726.	0.6	1
116	Incidence of Hemolytic Events after Exposure to Triggering Medications in Pediatric Patients with G6PD Deficiency. <i>Blood</i> , 2016, 128, 4810-4810.	0.6	1
117	Analysis of the Frequency of Spontaneous, Functionally-Significant Mutations in Genes Associated with Platelet Disorders in > 120,000 Healthy Individuals. <i>Blood</i> , 2018, 132, 2438-2438.	0.6	1
118	Racial Variation in ITP Prevalence and Rate of Chronic Disease Suggests Biological Differences. <i>Blood</i> , 2019, 134, 387-387.	0.6	1
119	The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis. <i>Blood</i> , 2019, 134, 2174-2174.	0.6	1
120	Dose Escalation Trial of Desulfated Heparin (ODSH) in Septic Peritonitis. <i>Frontiers in Veterinary Science</i> , 2022, 9, 862308.	0.9	1
121	Cover Image, Volume 176A, Number 10, October 2018. , 2018, 176, i-i.		0
122	The Treatment of Immune Thrombocytopenia. , 2018, , 45-80.		0
123	EVALUATION OF A CLINICAL PRACTICE PATHWAY FOR THE MANAGEMENT OF ACUTE CATHETER-RELATED VENOUS THROMBOEMBOLISM IN PEDIATRIC CARDIOLOGY PATIENTS: YEAR FOUR REVIEW. <i>Journal of the American College of Cardiology</i> , 2019, 73, 628.	1.2	0
124	Inherited Thrombocytopenias. , 2019, , 849-861.		0
125	Congenital Thrombocytopenia. , 2019, , 571-580.		0
126	Platelet Factor 4 Regulates Platelet Count In Vivo: Implications for Platelet Recovery after Cytotoxic Therapy.. <i>Blood</i> , 2005, 106, 3144-3144.	0.6	0



#	ARTICLE	IF	CITATIONS
127	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. Blood, 2010, 116, 2509-2509.	0.6	0
128	Influence Of Updated ASH Guidelines On Practice Patterns In Management Of Newly Diagnosed Childhood ITP, 2007-2012. Blood, 2013, 122, 772-772.	0.6	0
129	Detecting 22q11.2 Deletion Syndrome Using Flow Cytometry. Blood, 2014, 124, 4207-4207.	0.6	0
130	Conditional Knockout of LRP1 in Murine Megakaryocytes and Its Affects on Platelet Factor 4 Biology in Megakaryocytes. Blood, 2014, 124, 4150-4150.	0.6	0
131	Physician Factors Determining Treatment Decisions in Selecting Second Line Agents for Pediatric ITP. Blood, 2016, 128, 1008-1008.	0.6	0
132	Expression Differences Distinguish Pediatric Acute and Chronic ITP Using RNA Sequencing. Blood, 2018, 132, 127-127.	0.6	0
133	Comparison of LTA Versus Wbila in Pediatric Patients with Suspected Platelet Function Disorders. Blood, 2018, 132, 3762-3762.	0.6	0
134	Targeting Immune Dysregulation in Childhood Evans Syndrome. Blood, 2018, 132, 3564-3564.	0.6	0
135	The Role of PF4 Antibodies in Pediatric Sars-Cov-2 Infections. Blood, 2021, 138, 1004-1004.	0.6	0
136	Immature Platelet Fraction Does Not Correlate with Treatment Response in Immune Thrombocytopenia. Blood, 2021, 138, 1024-1024.	0.6	0
137	Anxiety in Adult Patients Living with ITP Stratified across Different Treatment Types and Groups. Blood, 2020, 136, 18-18.	0.6	0
138	Evidence of Microangiopathy in Children with Sars-Cov-2 Regardless of Clinical Presentation. Blood, 2020, 136, 28-29.	0.6	0
139	Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method. Blood, 2020, 136, 6-8.	0.6	0